AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Frequently asked questions
What sector does AEON Biopharma Inc. (AEON) operate in?
AEON Biopharma Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is AEON Biopharma Inc. (AEON) current stock price?
As of the latest data, AEON Biopharma Inc. stock price is $0.24, with a previous close of $0.24. AEON Biopharma Inc. gained $0.01 in the last trading session, representing a 2.08% increase.
What is AEON Biopharma Inc. (AEON) current market capitalization?
AEON Biopharma Inc. market cap is approximately 12.22 million.
What is AEON Biopharma Inc. (AEON) Earnings Per Share (EPS)?
The trailing EPS is -$4.55, and the forward EPS is -$0.27.
What is AEON Biopharma Inc. (AEON) EBITDA?
AEON Biopharma Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.91 million.
Does AEON Biopharma Inc. (AEON) pay dividends?
No. AEON Biopharma Inc. does not pay a dividend.
What is AEON Biopharma Inc. (AEON) beta (volatility) score?
AEON Biopharma Inc. has a beta of 0.652, indicating lower volatility than the overall market.